GAMMA Investing’s Rigel Pharmaceuticals RIGL Stock Holding History

GAMMA Investing’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$45.5K	Buy	945 +13	+1%	+$564	﹤0.01%	2428
2026 Q2	$36.5K	Sell	932 -5	-0.5%	-$154	﹤0.01%	2511
2026 Q1	$25.3K	Buy	937 +19	+2%	+$638	﹤0.01%	2597
2025 Q4	$39.3K	Buy	918 +37	+4%	+$1.4K	﹤0.01%	2229
2025 Q3	$25K	Buy	881 +3	+0.3%	+$90	﹤0.01%	2414
2025 Q2	$16.4K	Sell	878 -87	-9%	-$1.65K	﹤0.01%	2558
2025 Q1	$17.4K	Buy	965 +881	+1,049%	+$17.9K	﹤0.01%	2473
2024 Q4	$1.41K	Buy	84 +30	+56%	+$575	﹤0.01%	3326
2024 Q3	$874	Buy	+54	New	+$635	﹤0.01%	3291

Other funds holding RIGL

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

GAMMA Investing's RIGL Position: Q3 2026 in Review

GAMMA Investing increased its Rigel Pharmaceuticals (RIGL) stake by 1.4% in Q3 2026, buying an estimated $564 and bringing the position to 945 shares worth $45.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

GAMMA Investing first reported a position in RIGL in Q3 2024 and has held it in 9 quarters since. 12 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

GAMMA Investing held 945 shares of Rigel Pharmaceuticals worth $45.5K as of Q3 2026.
GAMMA Investing bought 13 Rigel Pharmaceuticals shares in Q3 2026, an estimated $564.
Rigel Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2428 holding.
GAMMA Investing first reported a position in Rigel Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
12 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.